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95%CRI:0.58–0.88) and alendronate (OR = 0.80, 95%CRI:0.70–0.91) compared to 
placebo were statistically signiﬁcant, while those for ibandronate (OR = 0.91, 
95%CRI:0.41–2.09) and etidronate (OR = 0.95, 95%CRI:0.44–2.12) were not. When 
the treatments were compared directly to each other, none of the treatments were 
statistically more effective than others. CONCLUSIONS: Overall, zoledronate 
appeared to be most effective at reducing fractures in women with postmenopausal 
osteoporosis.
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OBJECTIVES: Budgetary impact modeling often occurs early, amidst uncertainty 
surrounding the eligible patient population or the ﬁnal price of a new intervention. 
Uncertainty can be characterized using per-member per-month (PMPM) iso-curves 
that graphically depict the net budgetary impact at different prices and population 
sizes. The objective of this study is to examine the use of PMPM budgetary impact 
(PMPMBI) iso-curves to represent budgetary uncertainty for products prior to regula-
tory approval, using denosumab as an example. METHODS: A 3-year Markov cohort 
budgetary impact model (BIM) was developed for denosumab in the treatment of 
postmenopausal osteoporosis in a hypothetical US managed care plan. The model 
incorporates current market shares and persistence on osteoporosis treatments, and 
calculates the net impact of adding denosumab to the health plan. Direct costs include 
drug costs and medical cost offsets due to reductions in osteoporotic fractures. The 
model was used to construct PMPMBI iso-curves for each of the 3 model years by 
systematically varying the price of denosumab and the number of patients receiving 
treatment while holding all other parameters constant. RESULTS: In year 1, the 
PMPMBI iso-curves ranged from $−0.06 to $0.08 using the lower and upper limits 
of price and population size assumptions. The lower iso-curves occur at lower prices 
and/or population sizes and vice versa. Budget impact is insensitive to the size of the 
patient population when the price of denosumab is equal to the weighted average price 
of all other interventions. CONCLUSIONS: Iso-curves can be used to concisely report 
BIM results over a wide range of price and population size assumptions. The budgetary 
impact of denosumab can easily be interpolated once price and population size are 
known, allowing decision-makers to estimate PMPM costs soon after product 
approval.
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OBJECTIVES: Medical costs followed by incidents within hospitals are not linked 
with primary diseases and might be paid by hospitals. In that manner, it is very 
important for hospital managers to recognize the actual situation of medical costs for 
incidents. Cases injured with over the level two and their medical costs for a year are 
explored. METHODS: There are 2,866 incident reports in 2007 collected at Saint 
Mary’s Hospital in Kurume-City, Fukuoka, Japan. Their reports include 734 cases for 
Falls/Slips and 2,132 cases for others. The cases for Falls/Slips are classiﬁed 474 with 
level 1, 320 with level 2, and 136 with level 3a, and 14 with level 3b, respectively. 
Of the 14 cases with level 3a included three femoral neck fractures and femoral tro-
chanteric fractures each, and one femoral shaft fracture, facial fracture, clavicle frac-
ture, shoulder fracture, upper extremity fracture, lower extremity fracture, thoracic 
vertebral fracture, and traumatic subarachnoid hemorrhage,each. RESULTS: Accord-
ing to the injury level, average medical costs are 88 dollars (level 2, 59 cases), 94 
dollars (level 3a, 86 cases), and 12,330 dollars (level 3b, 14 cases). Medical costs with 
level 2 and 3a are directly calculated from the medical fee schedule under the social 
insurance system. By contrast, medical costs with level 3b are alternated by the average 
medical fee of the same diseases at the hospital, because we can not separate medical 
costs for injury by incidents and for primary diseases. For example, averaged medical 
cost for femoral neck fracture is 18,400 dollars by calculating 182 cases with same 
diseases were treated at our hospital. CONCLUSIONS: Total amount of medical costs 
for Falls/Slips is about 19 million dollars at our hospital for the year of 2007. There-
fore, Hospital administrators have to take appropriate measures to prevent patients 
from Falls/Slips and save money, because this amount is not overlooked.
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OBJECTIVES: The objective of this study was to build a decision analytic model to 
estimate the cost and effectiveness of allopurinol 300 mg/d and febuxostat 80 mg/d 
as a ﬁrst line treatment for gout patients based on available clinical and cost data. 
METHODS: We built a decision analytic model as a decision tree using TreeAge Pro 
2009, in which allopurinol was compared to febuxostat as a ﬁrst line treatment for 
gout. The model examined two time horizons: 1–8 weeks and 9–52 weeks. Treatment 
success from week 1–8 was deﬁned as no case of gout ﬂare. If a gout ﬂare occurred 
within week 1–8 there was an equal chance of continuing on treatment or switching 
to the alternative treatment strategy during weeks 9–52. During weeks 9–52 treatment 
failure occurred with report of a gout ﬂare. Treatment failure due to gout ﬂare was 
assumed to result in an additional physician visit. Costs of adverse events (musculo-
skeletal, joint-related signs and symptoms, liver function test abnormalities) from 
treatment were accounted for and assumed to result in a doctor visit. Data used to 
construct the economic model were derived from published clinical trials as well as 
available sources of physician and drug costs. Sensitivity analyses were preformed to 
assess the impact of variations on all model inputs. RESULTS: Total cost of allopu-
rinol as a ﬁrst line treatment for gout was $1125 compared to $7737 for febuxostat 
as a ﬁrst line treatment for gout. Sensitivity analyses indicate the model is most sensi-
tive to pill price. All else equal, a monthly supply of febuxostat would need to cost 
less then $3 to be as cost-effective as allopurinol. CONCLUSIONS: Allopurinol was 
$6612 less as a ﬁrst line treatment compared to febuxostat and therefore the cost 
effective treatment and as such should remain a ﬁrst line treatment.
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OBJECTIVES: Historical comparative cost analyses have included adalimumab 
(ADA), etanercept (ETA), and inﬂiximab (IFX). More recently, certolizumab pegol 
(CTP) and golimumab (GLM) have been FDA-approved for use in RA. The objective 
of this analysis was to estimate and compare annual drug and treatment costs of all 
anti-TNF agents approved for use in RA based on FDA-approved prescribing informa-
tion. METHODS: A cost analysis was conducted using FDA-approved prescribing 
information to calculate cumulative dose and administration schedule over a 12-month 
time horizon. Wholesale acquisition costs were obtained from First Databank for 
December 2009, with annual costs computed using labeled dosing. ADA cost was 
based on 26 injections of 40 mg every other week. CTP cost was calculated based on 
15 injections of 400 mg (weeks 0, 2, and 4 loading doses and 400 mg every 4 weeks 
maintenance dosing). ETA cost was based on 52 injections of 50 mg once weekly. 
GLM cost was based on 12 injections of 50 mg once monthly. IFX cost was calculated 
based on 100 mg vials for initial dosing of 3 mg/kg (75 kg patient) with dose increase 
to 5 mg/kg at 6 months (weeks 0, 2, and 6 loading doses with every 8 week mainte-
nance infusions; infusion fee = $181.05 per infusion from 2009 CMS Physician Fee 
Schedule). Costs of adverse events and concomitant methotrexate were assumed 
equivalent across all agents. A sensitivity analysis was conducted to assess impact of 
average sales price (ASP) on results. RESULTS: Annual drug only costs were $19,812 
(ADA), $21,940 (CTP), $20,190 (ETA), $19,824 (GLM), and $16,306 (IFX). Includ-
ing administration fees for infusion, the annual treatment cost of IFX was $17,754. 
A sensitivity analysis using ASP + 6% yielded similar results. CONCLUSIONS: Annual 
treatment costs of anti-TNF agents, including newer agents, are comparable when 
used for RA patients according to label.
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OBJECTIVES: To compare, between European and Latin American countries, the list 
prices of brands for the most expensive drugs in Colombia (Imatinib, Abacavir + 
Zidovudine + Lamivudine, Docetaxel, Etanercept, Filgrastim, Gemcitabine, Inﬂix-
imab, Interferon Beta 1 A, Interferon Beta1 B, Leuprolide, Lopinavir + Ritonavir, 
Mycophenolate, Octreotide, Paclitaxel, Somatotropin and Temozolamide). 
METHODS: We searched for list prices of the 16 most expensive drugs, as charged 
to the Colombian state, from 21 manufacturers in 10 countries. In Europe: Belgium, 
Spain and the UK were analyzed, while in Latin America: Chile, Colombia, Ecuador, 
Paraguay, Peru and Uruguay were studied. For the data analysis, UK list prices were 
used as the standard. RESULTS: For comparison purposes, we selected 21 manufac-
turers offering these high-cost medications in the 10 countries analyzed, leading to a 
pool of 210 potential market prices. Out of them, 142 were obtained (we had the 21 
for the UK). A total of 101 prices (71.1%) are higher than those in the UK. Average 
prices are 168.5% (SD0.99) of the UK price. The average for Latin American countries 
was 197.4% (SD1.13) of the UK price, and 118.6% (SD 0.31) for the European 
countries. The country with the highest average is Uruguay (294.7% UK price, 
SD0.95), followed by Colombia (278.5% UK price, SD1.13). The country with the 
lowest average is our standard, the UK (SD 100.0%), followed by Ecuador (105.1% 
UK price, SD 0.4). CONCLUSIONS: We found a signiﬁcant difference between 
average prices in Europe and Latin America, the latter being much higher than the 
UK standards. If UK prices were used in Latin America, it would be possible to treat 
twice as many patients as are currently treated. In Colombia, based on the information 
available, around US$ 67 Million could be saved if UK prices were charged, assuming 
that purchases are made at list prices.
